An Open Label, Multi-center, IRESSA™ Clinical Access Program of Gefitinib 250 mg (IRESSA™ ) for the Continued Treatment of Patients in the United States Currently Benefiting or Who Have Benefited From Treatment with Gefitinib

Service: Trial Number:
004-11
Principal Investigator: Conducted at:
Orange Coast Memorial
Currently enrolling additional patients:
Yes
Age Range:
18 years & up

This study will provide continued access to Gefitinib (Iressa) to United States patients who are currently receiving and benefiting or have previously benefited from treatment with Gefitinib under the IRE SSA™ Access Program (held under NDA 21-399) as well as patients who are currently benefiting or have benefited from treatment with Gefitinib through a clinical trial that was IRB approved prior to 17 June 2005 under the current IND (54,576) following closure of the current NDA (21-399).

MemorialCare Research Center Contact Form

For further information about this study or to express your interest in this study, please fill out and submit this form.
Address
,
 
The email to associate with this registration.